KR20240055097A - 니르세비맙을 사용한 호흡기 세포융합 바이러스 하기도 감염의 예방 - Google Patents
니르세비맙을 사용한 호흡기 세포융합 바이러스 하기도 감염의 예방 Download PDFInfo
- Publication number
- KR20240055097A KR20240055097A KR1020247011813A KR20247011813A KR20240055097A KR 20240055097 A KR20240055097 A KR 20240055097A KR 1020247011813 A KR1020247011813 A KR 1020247011813A KR 20247011813 A KR20247011813 A KR 20247011813A KR 20240055097 A KR20240055097 A KR 20240055097A
- Authority
- KR
- South Korea
- Prior art keywords
- rsv
- nirsevimab
- subject
- dose
- months
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C07K16/1027—
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/11—Paramyxoviridae (F); Pneumoviridae (F), e.g. respiratory syncytial virus [RSV]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—RNA viruses
- C07K16/102—Coronaviridae (F)
- C07K16/104—Severe acute respiratory syndrome coronavirus 2 [SARS‐CoV‐2]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Oncology (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pulmonology (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163261117P | 2021-09-13 | 2021-09-13 | |
| US63/261,117 | 2021-09-13 | ||
| US202263266594P | 2022-01-10 | 2022-01-10 | |
| US63/266,594 | 2022-01-10 | ||
| US202263363633P | 2022-04-26 | 2022-04-26 | |
| US63/363,633 | 2022-04-26 | ||
| US202263364554P | 2022-05-11 | 2022-05-11 | |
| US63/364,554 | 2022-05-11 | ||
| PCT/US2022/076311 WO2023039584A2 (en) | 2021-09-13 | 2022-09-12 | Prevention of respiratory syncytial virus lower respiratory tract infection with nirsevimab |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240055097A true KR20240055097A (ko) | 2024-04-26 |
Family
ID=83508746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247011813A Pending KR20240055097A (ko) | 2021-09-13 | 2022-09-12 | 니르세비맙을 사용한 호흡기 세포융합 바이러스 하기도 감염의 예방 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20250340622A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4402166A2 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024535009A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20240055097A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022341188A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3229901A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL310974A (cg-RX-API-DMAC7.html) |
| TW (1) | TW202340237A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2023039584A2 (cg-RX-API-DMAC7.html) |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS60387B1 (sr) | 2014-01-15 | 2020-07-31 | Medimmune Llc | Rsv-specifična antitela i njihovi funkcionalni delovi |
| US12024553B2 (en) * | 2019-04-30 | 2024-07-02 | Medimmune Limited | Dosage regimens for and compositions including anti-RSV antibodies |
-
2022
- 2022-09-12 KR KR1020247011813A patent/KR20240055097A/ko active Pending
- 2022-09-12 TW TW111134404A patent/TW202340237A/zh unknown
- 2022-09-12 IL IL310974A patent/IL310974A/en unknown
- 2022-09-12 AU AU2022341188A patent/AU2022341188A1/en active Pending
- 2022-09-12 WO PCT/US2022/076311 patent/WO2023039584A2/en not_active Ceased
- 2022-09-12 CA CA3229901A patent/CA3229901A1/en active Pending
- 2022-09-12 US US18/691,361 patent/US20250340622A1/en active Pending
- 2022-09-12 EP EP22783259.9A patent/EP4402166A2/en active Pending
- 2022-09-12 JP JP2024515936A patent/JP2024535009A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2023039584A2 (en) | 2023-03-16 |
| WO2023039584A3 (en) | 2023-04-06 |
| CA3229901A1 (en) | 2023-03-16 |
| IL310974A (en) | 2024-04-01 |
| US20250340622A1 (en) | 2025-11-06 |
| AU2022341188A1 (en) | 2024-03-14 |
| EP4402166A2 (en) | 2024-07-24 |
| JP2024535009A (ja) | 2024-09-26 |
| TW202340237A (zh) | 2023-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Rodriguez-Fernandez et al. | Monoclonal antibodies for prevention of respiratory syncytial virus infection | |
| JP7851613B2 (ja) | 抗SARS-CoV-2スパイク糖タンパク質抗体を用いてSARS-CoV-2感染及びCOVID-19を治療又は予防するための方法 | |
| Fenton et al. | Palivizumab: a review of its use as prophylaxis for serious respiratory syncytial virus infection | |
| US12565526B2 (en) | Formulations of anti-RSV antibodies and methods of use thereof | |
| SG11202111748TA (en) | Dosage regimens for and compositions including anti-rsv antibodies | |
| EUA | Fact sheet for healthcare providers: emergency use authorization for evusheld™(tixagevimab co-packaged with cilgavimab) | |
| Welliver | Respiratory syncytial virus immunoglobulin and monoclonal antibodies in the prevention and treatment of respiratory syncytial virus infection | |
| WO2021260692A1 (en) | Compositions and methods for treating infectious disease caused by coronavirus | |
| US20250340622A1 (en) | Prevention of respiratory syncytial virus lower respiratory tract infection with nirsevimab | |
| EA053309B1 (ru) | Предупреждение инфекции нижнего респираторного тракта, вызываемой респираторно-синцитиальным вирусом, с помощью нирсевимаба | |
| CN118302441A (zh) | 尼塞韦单抗预防呼吸道合胞病毒下呼吸道感染 | |
| RU2807524C2 (ru) | Составы антител к rsv и способы их применения | |
| CA3115708C (en) | Formulations of anti-rsv antibodies and methods of use thereof | |
| KR102703936B1 (ko) | 과도한 유리형 light를 포함하는 방법 및 치료 | |
| WO2023081434A2 (en) | Methods for treating or preventing sars-cov-2 infections and covid-19 with anti-sars-cov-2 spike glycoprotein antibodies | |
| WO2026080293A1 (en) | Anti-human rsv f protein antibodies for use in treatment or prophylaxis | |
| KR20220010456A (ko) | 사스-코로나바이러스 감염증을 예방 또는 치료하기 위한 투여 요법 | |
| KR20220010411A (ko) | 사스-코로나바이러스 감염증을 예방 또는 치료하기 위한 투여 요법 | |
| CN120513100A (zh) | 一种tslp抗体治疗哮喘的方法 | |
| KR20220010410A (ko) | 사스-코로나바이러스 감염증을 예방 또는 치료하기 위한 투여 요법 | |
| CN120000779A (zh) | 抗il-5抗体治疗与嗜酸性粒细胞升高相关疾病的用途 | |
| WO2021005232A1 (en) | Intranasal administration of neutralising antiviral antibodies | |
| KR20220010402A (ko) | 사스-코로나바이러스 감염증을 예방 또는 치료하기 위한 투여 요법 | |
| Kneyber et al. | Respiratory Syncytial Virus (RSV) in the Pediatric Intensive Care Unit | |
| Fernández et al. | Research article A phase 2, randomized, double-blind safety and pharmacokinetic assessment of respiratory syncytial virus (RSV) prophylaxis with motavizumab and palivizumab administered in the same season |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P22-X000 | Classification modified |
St.27 status event code: A-2-2-P10-P22-nap-X000 |
|
| PN2301 | Change of applicant |
St.27 status event code: A-3-3-R10-R13-asn-PN2301 St.27 status event code: A-3-3-R10-R11-asn-PN2301 |
|
| R11 | Change to the name of applicant or owner or transfer of ownership requested |
Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R11-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| R13 | Change to the name of applicant or owner recorded |
Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R13-ASN-PN2301 (AS PROVIDED BY THE NATIONAL OFFICE) |